Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patupilone plus prednisone versus docetaxel plus prednisone in metastatic hormone-refractory prostate cancer
2006-001822-23Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Patupilone plus prednisone with Docetaxel plus prednisone (2 arms). Primary endpoints: PSA response and Measurable soft tissue disease response. Started Jun 2006; status: completed.
02
Drugs
patupilonedocetaxelprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-001822-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001822-23.